Startup Dossier
Primaa
Paris-based MedTech startup developing AI-powered diagnostic software for histology and cancer detection. Primaa’s CE-marked solution Cleo Breast automates the detection and quantification of key biomarkers in breast cancer, while Cleo Skin—in the process of CE marking—targets melanoma, squamous cell carcinoma, and basal cell carcinoma. Its tools enhance diagnostic accuracy, reduce processing time, and alleviate pathologists’ workloads.
About
Paris-based MedTech startup developing AI-powered diagnostic software for histology and cancer detection. Primaa’s CE-marked solution Cleo Breast automates the detection and quantification of key biomarkers in breast cancer, while Cleo Skin—in the process of CE marking—targets melanoma, squamous cell carcinoma, and basal cell carcinoma. Its tools enhance diagnostic accuracy, reduce processing time, and alleviate pathologists’ workloads.
Structural DNA
Legal Name
Primaa
SIREN
842567422
Funding Lineage
Other
Swen Capital (Lead)
€7.0M
Nov 2025
Programs
i-Nov